Nongenomic estrogen signaling and that interactions
with the epidermal growth issue receptor
signaling pathway in an exceedinglyddition to the nuclear mechanisms
of er action like increased cell proliferation and gene transcription,
estrogens will too rapidly activate signaling in seconds
to minutes. these rapid signaling effects are usually said as
nongenomic effects and are thought to occur via ers located
within the membrane ( fig. 25. five ). in human breast cancer cells, this
membrane receptor was identified as a g-protein–coupled receptor
known as gpr30. 103, 104 in nsclc cells, extranuclear ers have
been identified in plasma membrane fractions and are
shown to promote rapid stimulation of signaling pathways. 105
these effects is inhibited by the addition of fulvestrant.
current work is focusing on the role of gpr30 in nsclc.
nongenomic er signaling acts in concert with growth factor
signaling pathways, such because the epidermal growth issue receptor
( egfr/her-1 ). egfr could be a member of the tyrosine kinase receptor
family that too includes her-2, her-3, and her-4. 106
these receptors are implicated in proliferation, cell motility,
angiogenesis, cell survival, and differentiation. 107 clinically, overexpression
of egfr correlates with poor prognosis in nsclc
patients. 79, 108 furthermore, combined overexpression of egfr
and er correlates was demonstrated to be an freelance indicator
of poorer prognosis in lung cancer, consistent with cross talk
between these 2 pathways. 79
an interaction between the er and egfr has been demonstrated
in lung cancer cells. 94, 109 during this regard, estrogen can
rapidly activate the egfr in lung cancer cell lines ( liganddependent
signaling ) and also the combination of fulvestrant and
gefitinib, an egfr tyrosine kinase inhibitor ( tki ), in nsclc
will maximally inhibit cell proliferation, induce apoptosis and
affect downstream signaling pathways each in vitro and that in
vivo. 94 the additional clinically relevant egfr tki, erlotinib, also
gave superior antitumor activity in nsclc tumor xenograft
experiments when used in combination with fulvestrant compared
to single-agent therapy. 109 furthermore, membrane ers
were found to be colocalized with egfr in lung tumors. 105
ligand-independent nongenomic signaling will too occur. in
this regard, egfr might directly phosphorylate er at specific
serine residues. a hundred and ten these residues were found to be phosphorylated
in 87. 5% of er-positive lung tumors examined. 109
a reciprocal management mechanism was too observed between
er and egfr in lung cancer cells. during this respect, egfr protein
expression was downregulated in response to estrogen and
upregulated in response to fulvestrant in vitro, suggesting that
the egfr pathway could be activated when estrogen is depleted. 94
conversely, er protein expression was downregulated in response
to egf and upregulated in response to gefitinib providing
a rationale to target these 2 pathways simultaneously. 94
targeting the egfr through tiny molecule tkis is of
limited use within the absence of an egfr mutation, that only
occurs in an exceedingly minority of patients. interestingly, the patients
who respond to egfr tkis are mainly girls and neversmokers.
111 recently, a phase i clinical trial using medication that
target these 2 signaling pathways was performed to assess the
toxicity of combined treatment of gefitinib with fulvestrant in
22 postmenopausal girls. 112 targeting each pathways was
found to be safe and have antitumor activity in girls with
stage iiib/iv nsclc. additionally, immunohistochemical
staining of nuclear er was correlated with improved patient
survival. phase ii trials examining the combination of erlotinib
with fulvestrant are too underway. targeting the estrogen signaling
pathway via each nuclear and extranuclear receptors in
conjunction with the egfr signaling pathway ought to have
increased beneficial antitumor effects in nsclc as has been
observed in breast cancer cells. 113 combination therapy may
increase the duration of response in patients whose tumors
harbor an egfr mutation moreover as an improved response in
patients whose tumors don't contain an egfr mutation.
with the epidermal growth issue receptor
signaling pathway in an exceedinglyddition to the nuclear mechanisms
of er action like increased cell proliferation and gene transcription,
estrogens will too rapidly activate signaling in seconds
to minutes. these rapid signaling effects are usually said as
nongenomic effects and are thought to occur via ers located
within the membrane ( fig. 25. five ). in human breast cancer cells, this
membrane receptor was identified as a g-protein–coupled receptor
known as gpr30. 103, 104 in nsclc cells, extranuclear ers have
been identified in plasma membrane fractions and are
shown to promote rapid stimulation of signaling pathways. 105
these effects is inhibited by the addition of fulvestrant.
current work is focusing on the role of gpr30 in nsclc.
nongenomic er signaling acts in concert with growth factor
signaling pathways, such because the epidermal growth issue receptor
( egfr/her-1 ). egfr could be a member of the tyrosine kinase receptor
family that too includes her-2, her-3, and her-4. 106
these receptors are implicated in proliferation, cell motility,
angiogenesis, cell survival, and differentiation. 107 clinically, overexpression
of egfr correlates with poor prognosis in nsclc
patients. 79, 108 furthermore, combined overexpression of egfr
and er correlates was demonstrated to be an freelance indicator
of poorer prognosis in lung cancer, consistent with cross talk
between these 2 pathways. 79
an interaction between the er and egfr has been demonstrated
in lung cancer cells. 94, 109 during this regard, estrogen can
rapidly activate the egfr in lung cancer cell lines ( liganddependent
signaling ) and also the combination of fulvestrant and
gefitinib, an egfr tyrosine kinase inhibitor ( tki ), in nsclc
will maximally inhibit cell proliferation, induce apoptosis and
affect downstream signaling pathways each in vitro and that in
vivo. 94 the additional clinically relevant egfr tki, erlotinib, also
gave superior antitumor activity in nsclc tumor xenograft
experiments when used in combination with fulvestrant compared
to single-agent therapy. 109 furthermore, membrane ers
were found to be colocalized with egfr in lung tumors. 105
ligand-independent nongenomic signaling will too occur. in
this regard, egfr might directly phosphorylate er at specific
serine residues. a hundred and ten these residues were found to be phosphorylated
in 87. 5% of er-positive lung tumors examined. 109
a reciprocal management mechanism was too observed between
er and egfr in lung cancer cells. during this respect, egfr protein
expression was downregulated in response to estrogen and
upregulated in response to fulvestrant in vitro, suggesting that
the egfr pathway could be activated when estrogen is depleted. 94
conversely, er protein expression was downregulated in response
to egf and upregulated in response to gefitinib providing
a rationale to target these 2 pathways simultaneously. 94
targeting the egfr through tiny molecule tkis is of
limited use within the absence of an egfr mutation, that only
occurs in an exceedingly minority of patients. interestingly, the patients
who respond to egfr tkis are mainly girls and neversmokers.
111 recently, a phase i clinical trial using medication that
target these 2 signaling pathways was performed to assess the
toxicity of combined treatment of gefitinib with fulvestrant in
22 postmenopausal girls. 112 targeting each pathways was
found to be safe and have antitumor activity in girls with
stage iiib/iv nsclc. additionally, immunohistochemical
staining of nuclear er was correlated with improved patient
survival. phase ii trials examining the combination of erlotinib
with fulvestrant are too underway. targeting the estrogen signaling
pathway via each nuclear and extranuclear receptors in
conjunction with the egfr signaling pathway ought to have
increased beneficial antitumor effects in nsclc as has been
observed in breast cancer cells. 113 combination therapy may
increase the duration of response in patients whose tumors
harbor an egfr mutation moreover as an improved response in
patients whose tumors don't contain an egfr mutation.
0 komentar:
Posting Komentar